Rachel Hetzner
Primary Care · Madison Heights, MINPI 1154729960
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 414 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 414 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- Lilly USA, LLC$667
- GSK$574
- AbbVie$483
- Pfizer$431
- plus $2K from 27 others
What the payments were for
- Food & beverage$7,573100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 107 | $1,656 |
| AstraZeneca(2 entities) | 52 | $1,353 |
| Lilly USA, LLC | 44 | $667 |
| GSK | 36 | $574 |
| AbbVie | 27 | $483 |
| Pfizer | 24 | $431 |
| Amgen | 15 | $387 |
| Boehringer Ingelheim | 22 | $374 |
| Abbott | 12 | $266 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $257 |
| Exact Sciences | 7 | $151 |
| Axsome Therapeutics, Inc. | 6 | $128 |
| Bausch Health US, LLC | 8 | $128 |
| Astellas Pharma US Inc | 6 | $124 |
| Lundbeck LLC | 4 | $78 |
| Mylan Specialty L.p. | 3 | $64 |
| Novartis | 3 | $49 |
| Bayer | 3 | $43 |
| Amarin Pharma, Inc. | 3 | $43 |
| Merck | 3 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Johnson & Johnson | 2 | $26 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Nevro Corp. | 1 | $24 |
| Abiomed | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Pulmonx Corporation | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Alkermes, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,573 in reported general payments places this provider in the 95th percentile of 292 primary care providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 61 | $77,115 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 69 | $56,680 |
| TrulicityDulaglutide | 44 | $48,460 |
| JanuviaSitagliptin Phosphate | 34 | $33,119 |
| OzempicSemaglutide | 26 | $27,969 |
| EliquisApixaban | 18 | $21,024 |
| XareltoRivaroxaban | 13 | $18,518 |
| LinzessLinaclotide | 19 | $17,051 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $12,033 |
| FarxigaDapagliflozin Propanediol | 12 | $11,265 |
| Varenicline Tartrate | 14 | $4,126 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $2,628 |
| Atorvastatin Calcium | 197 | $2,152 |
| Lisinopril | 276 | $1,928 |
| Losartan Potassium | 136 | $1,901 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $374 | $77,11561 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $574 | $68,71391 claims |
| Lilly USA, LLCTrulicity | $667 | $48,46044 claims |
| MerckJanuvia | $38 | $33,11934 claims |
| Novo NordiskOzempic | $1,656 | $27,96926 claims |
| PfizerEliquis | $431 | $21,02418 claims |
| Johnson & JohnsonXarelto | $26 | $18,51813 claims |
| AbbVieLinzess | $483 | $17,05119 claims |
| AstraZenecaFarxiga | $1,353 | $11,26512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 292 primary care providers in Michigan.
Other primary care in Madison Heights
- Donna HamillGrosse Pointe$17K
- Marie Sighe-NzokouLansing$16K
- Alexandria SchwabBay City$10K
- Amy HenryRochester Hills$10K
- Claire GebaraWaterford$9K
- Vanita RobinsonDetroit$9K
- Mary BoudreauMason$9K
- Kimberly FrazierLansing$8K
- Katherine HouleMarquette$7K
- Susan ArmstrongWyandotte$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.